利培酮联合阿立哌唑治疗精神分裂症临床效果及安全性

Clinical efficacy and safety of risperidone combined with aripiprazole in the treatment of schizophrenia

目的探讨利培酮联合阿立哌唑与单用利培酮治疗精神分裂症的效果及安全性。方法选择2019年1—12月在我院诊断治疗的精神分裂症患者60例为研究对象,随机分为观察组与对照组,每组各30例。观察组采用利培酮联合阿立哌唑治疗,对照组采用利培酮治疗,比较两组治疗前后PANSS评分、PSP评分、MMSE评分以及不良反应情况。结果(1)治疗后,两组PANSS评分均显著低于治疗前,差异有统计学意义(P<0.05);治疗后,观察组PANSS评分显著低于对照组,差异有统计学意义(P<0.05)。(2)治疗后,两组PSP评分均显著高于治疗前,差异有统计学意义(P<0.05);治疗后,观察组PSP评分显著高于对照组,差异有统计学意义(P<0.05)。(3)治疗后,两组MMSE评分均显著高于治疗前,差异有统计学意义(P<0.05);治疗后,观察组MMSE评分显著高于对照组,差异有统计学意义(P<0.05)。(4)两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论利培酮联合阿立哌唑治疗精神分裂症可显著改善临床症状,并且不增加不良反应发生情况。

Objective To investigate the efficacy and safety of risperidone combined with aripiprazole and risperidone alone in the treatment of schizophrenia.Methods A total of 60 patients with schizophrenia who were diagnosed and treated in our hospital from January to December 2019 were selected as the study subjects,and randomly divided into observation group and control group,with 30 cases in each group.The observation group was given risperidone combined with aripiprazole,and the control group was given risperidone.The PANSS score,PSP score and MMSE score were compared between the two groups before and after treatment,and the adverse reactions were compared between the two groups.Results(1)After treatment,the PANSS scores in the two groups were significantly lower than those before treatment,and the difference was statistically significant(P<0.05);after treatment,the PANSS score in the observation group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).(2)After treatment,the PSP scores in the two groups were significantly higher than those before treatment,and the difference was statistically significant(P<0.05);after treatment,the PSP score in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).(3)After treatment,the MMSE scores in the two groups were significantly higher than those before treatment,and the difference was statistically significant(P<0.05);after treatment,the MMSE score in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).(4)There was no statistically significant difference in the total incidence rate of adverse reactions between the two groups(P>0.05).Conclusion The combination of risperidone and aripiprazole in the treatment of schizophrenia can significantly improve the clinical symptoms without incurring adverse reactions.